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ABSTRACT
Estradiol (E2) is important for male skeletal health and the effect of E2 is mediated via estrogen receptor (ER)-a. This was demonstrated by
the findings that men with an inactivating mutation in aromatase or a nonfunctional ERa had osteopenia and continued longitudinal
growth after sexual maturation. The aim of the present study was to evaluate the role of different domains of ERa for the effects of E2 and
selective estrogen receptor modulators (SERMs) on bone mass in males. Three mouse models lacking either ERaAF-1 (ERaAF-10), ERaAF-
2 (ERaAF-20), or the total ERa (ERa/) were orchidectomized (orx) and treated with E2 or placebo. E2 treatment increased the trabecular
and cortical bone mass and bone strength, whereas it reduced the thymus weight and bone marrow cellularity in orx wild type (WT)
mice. These parameters did not respond to E2 treatment in orx ERa/ or ERaAF-20 mirx ERaAF-10 mice were tissue-dependent, with a
clear response in cortical bone parameters and bone marrow cellularity, but no response in trabecular bone. To determine the role of
ERaAF-1 for the effects of SERMs, we treated orx WT and ERaAF-10 mice with raloxifene (Ral), lasofoxifene (Las), bazedoxifene (Bza), or
vehicle. These SERMs increased total body areal bone mineral density (BMD) and trabecular volumetric BMD to a similar extent in orx WT
mice. Furthermore, only Las increased cortical thickness significantly and only Bza increased bone strength significantly. However, all
SERMs showed a tendency toward increased cortical bone parameters. Importantly, all SERM effects were absent in the orx ERaAF-10
mice. In conclusion, ERaAF-2 is required for the estrogenic effects on all evaluated parameters, whereas the role of ERaAF-1 is tissue-
specific. All evaluated effects of Ral, Las and Bza are dependent on a functional ERaAF-1. Our findings might contribute to the
development of bone-specific SERMs in males.  2013 American Society for Bone and Mineral Research.
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Introduction
Estrogen has previously been considered the female sexsteroid and testosterone the male sex steroid, but now there
are several studies, in both man and mouse, showing that
estradiol (E2) is of importance for male skeletal health.(1–4)
The importance of E2 in males was clearly demonstrated by the
finding that men with an inactivating mutation in the aromatase
gene had osteopenia and a continued linear growth after sexual
maturation.(5,6) A similar skeletal phenotype was found in a man
with a nonfunctional estrogen receptor (ER)-a. This indicates that
ERa is the main mediator of the skeletal effects of estrogen in
men.(7) In addition, it has been shown that ERa, but not ERb,
is required for the skeletal effects of estrogen in male mice.(8–12)
G protein-coupled ER-1 (GPER-1 or GPR30) has also been
suggested to be an ER, but we recently demonstrated that the E2
response on bone mass is independent of the GPER-1.(13) These
results, together with the fact that men have higher E2 levels
than postmenopausal women, suggest that E2 is a hormone of
importance for male bone health.(14,15)
ERa interacts with several classes of coactivators/corepressors
and the balance between coactivators and corepressors is
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dependent on the cell type.(4,16) The balance of cofactors is a
critical determinant of the ability of ERa to regulate gene
transcription. Therefore, estrogen can exert vastly diverse
effects in different tissues. In vitro studies have shown that
the estrogen-induced transactivation of ERa is mediated by the
ligand-independent activation function (AF)-1 and/or the ligand-
dependent AF-2 in ERa. This is dependent on the cell type
and promoter context,(17–19) and could depend on the cofactors
and/or balance of cofactors in the cell type evaluated. Several
cofactors bind to ERaAF-1 and ERaAF-2; some are specific for
either AF-1 or AF-2, whereas some cofactors bind to both.(20) It
has also been shown that the full ligand-dependent transcrip-
tional activity of ERa is reached through a synergism between
AF-1 and AF-2.(17–19,21–23) Variation in the expression of cofactors
and the recruitment of cofactors to the ERa in different cell types
also appear to have an important role for the tissue-specific
effects of the selective ER modulators (SERMs).(17,24) A SERM acts
as an ER agonist or antagonist in a tissue-specific manner.
Compared to E2, the SERMs have a bulky side chain, which upon
binding to ERa protrudes from the ligand-binding pocket. This
hinders the optimal conformational change of the ligand-
binding domain of ERa by preventing the folding of helix 12 in
the agonistic orientation. Consequently, ERaAF-2 is not formed
correctly, which prevents ERa from interacting with certain
cofactors.(17,24–26) From these in vitro studies it has, therefore,
been suggested that the effects of a specific SERM are mainly
mediated by the ERaAF-1 and other regions of ERa than ERa
AF-2, and that the importance of the different regions of ERa is
decided by the particular conformational change of ERa induced
by the SERM.(17,24–26)
Raloxifene (Ral), which was the first SERM approved for the
prevention and treatment of postmenopausal osteoporosis, was
shown to be an ER agonist in bone but an ER antagonist in
breast.(27–29) Today, two more SERMs; lasofoxifene (Las) and
bazedoxifene (Bza), are approved in Europe for treatment of
postmenopausal osteoporosis. These SERMs and Ral have similar
structures and they all reduce the risk for vertebral fractures.
In addition, Las and Bza have also been suggested to be more
effective in reducing the risk for nonvertebral fractures than
Ral.(27,29,30) Unfortunately, these three SERMs are all associated
with side effects; eg, an increased risk for thromboembo-
lism.(27,29–31) Ral treatment has been shown to increase the bone
mass in men with serum E2 levels below a certain threshold,
without having feminizing effects, but there is not yet any
approved SERM treatment available for male osteoporosis.(32,33)
Therefore, it is possible that bone-specific SERMs may be useful
in the treatment of male osteoporosis. Thus, it is of importance
to further characterize the signaling pathways of estrogen and
SERMs in the male bone.
In this study, we have evaluated the roles of ERaAF-1 and
ERaAF-2 in male mice for the effects of E2 in bone, and some
other major estrogen-responsive tissues by analyzing mice
with inactivation of the entire ERa protein (ERa/), ERaAF-1
(ERaAF-10), or ERaAF-2 (ERaAF-20). In addition, because in vitro
experiments have suggested that the ERaAF-1 is the main region
for mediating the tissue-specific effects of SERMs, we treated orx
wild-type (WT) and orx ERaAF-10 mice with Ral, Las, and Bza to
clarify the role of ERaAF-1 for the effects of these SERMs in vivo.
The results obtained will clarify the relevance of different regions
of the ERa for the effect of E2 and SERMs in males, thus
facilitating the design of novel bone-specific SERMs.
Materials and Methods
Generation of mice
All experimental procedures involving animals were approved
by the Ethics Committee of the University of Gothenburg.
The generation of ERa-deficient mice (ERa/),(34) ERaAF-10
mice,(35,36) and ERaAF-20 mice(36) have been described. Briefly,
the ERa/ mice have a deletion in exon 3 of the ERa gene and
they do not express any of the isoforms of the ERa protein.(34)
The ERaAF-10 mice have a specific deletion of AF-1 and do not
express any full-length 66-kDa protein. Instead, they express a
truncated 49-kDa ERa protein that lacks AF-1 and also the
physiologically occurring but less abundantly expressed 46-kDa
ERa isoform. The ERaAF-10 protein has been shown, in vivo, to
be expressed in similar amounts as the WT ERa protein.(35) The
ERaAF-20 mice have a deletion of the AF-2 core that resides
within exon 9 and corresponds to amino acids 543 to 549. The
sizes of the ERa proteins in ERaAF-20 mice are slightly smaller
than the WT ERa proteins of 66-kDa and 46-kDa, respectively,
and they have been shown, in vivo, to be expressed in similar
amounts as the WT ERa proteins.(36,37) All three mouse models
and their WT littermate controls were inbred C57BL/6 mice and
generated by breeding heterozygous females and males.
In the experiment where the importance of ERaAF-1 and
ERaAF-2 for an effect of estrogen was evaluated, orchidectomy
(orx) or sham operation was performed on 12-week-old ERa/,
ERaAF-10, ERaAF-20 and WT male mice. The orx mice were
treated with either placebo or E2 (167 ng/mouse/d) and the
sham-operated mice were treated with placebo for 4 weeks,
using slow-release pellets inserted subcutaneous (s.c.) at the
time of surgery (Innovative Research of America, Sarasota, FL,
USA; n¼ 8–11 per group).
In the experiment where the different SERMs were evaluated,
orx was performed on 20-week-old ERaAF-10 and WT male mice.
The orx mice rested for 6 days before they received s.c. injections
5 days/week during 3 weeks with either vehicle (veh; Miglyol
812; OmyaPeralta GmbH, Hamburg, Germany), raloxifene
(120mg/mouse/d; Sigma Aldrich, St. Louis, MO, USA), lasofox-
ifene (8mg/mouse/d; Pfizer Inc., Groton, CT, USA), or bazedox-
ifene (48mg/mouse/d; Pfizer) (n¼ 6–10 per group).
Measurement of serum hormone levels
Commercially available radioimmunoassay (RIA) kits were used
to assess serum concentrations of testosterone (ICN Biomedicals,
Costa Mesa, CA, USA), according to the manufacturer’s
instructions.
Dual-energy X-ray absorptiometry
Analyses of total body areal bone mineral density (aBMD) were
performed by dual-energy X-ray absorptiometry (DXA) using
the Lunar PIXImus mouse densitometer (Wipro GE Healthcare,
Madison, WI, USA).
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Peripheral quantitative computer tomography
Computer tomography scans were performed with the
peripheral quantitative computer tomography (pQCT) XCT
RESEARCH M (version 4.5B; Norland, Fort Atkinson, WI, USA),
operating at a resolution of 70mm as described.(38) The scans
were positioned in the metaphysic, at a distance proximal from
the distal growth plate of the femur corresponding to 3.4% of
the total length of the femur, and at a distance distal from the
proximal growth plate of the tibia corresponding to 2.6% of the
total length of the tibia. The trabecular bone region was defined
as the inner 45% of the total cross-sectional area. Cortical bone
parameters were analyzed in the mid-diaphyseal region of the
femur and tibia.(12)
Micro–computed tomography
Micro–computed tomography (mCT) analyses were performed
on the lumbar vertebra 5 (L5) by using Skyscan 1072 scanner
(Skyscan N.V., Aartselaar, Belgium), imaged with an X-ray tube
voltage of 100 kV and current 98mA, with a 1-mm aluminum
filter.(9) The scanning angular rotation was 180 degrees and the
angular increment 0.90 degrees. The voxel size was 6.51mm
isotropically. Datasets were reconstructed using a modified
Feldkamp algorithm and segmented into binary images using
adaptive local thresholding.(39) The trabecular bone in the
vertebral body caudal of the pedicles was selected for analyses as
described.(36)
Three-point bending
Immediately after the dissection, the femurs were fixed in
Bu¨rkhardt’s formaldehyde for 2 days and after that stored in 70%
ethanol. Just before the mechanical testing the bones were
rinsed in PBS for 24 hours. The three-point bending test (span
length 5.5mm, loading speed 0.155mm/sec) at the mid femur
wasmade by the Instron universal testingmachine (Instron 3366;
Instron Corp., Norwood, MA, USA). Based on the recorded
load deformation curves, the biomechanical parameters were
acquired from raw files produced by Bluehill 2 software version
2.6 (Instron) with custom-made Excel macros.
Bone marrow cellularity and cells
Bone marrow cells were harvested by flushing 5mL PBS through
the bone cavities of one femur and one humerus, from
each mouse, using a syringe. After centrifugation at 515 g for
5 minutes, pelleted cells were resuspended in Tris-buffered
0.83% NH4Cl solution (pH 7.29) for 5 minutes to lyse erythrocytes
and then washed in PBS. Bonemarrow cells were resuspended in
RPMI culture medium (PAA Laboratories, Pasching, Austria)
before use. The total number of leucocytes in bone marrow was
calculated using an automated cell counter (Sysmex, Hamburg,
Germany). For flow cytometry analyses, cells were stained
with phycoerythrin (PE)-conjugated antibodies to CD19
(Beckton-Dickinson, Biosciences, Pharmingen, San Diego, CA,
USA) for detection of B-lymphocytes. The cells were then
subjected to fluorescence activated cell sorter analysis (FACS)
on a FACSCalibur (Beckton-Dickinson, Biosciences, Pharmingen)
and analyzed using FlowJo software. Results are expressed as cell
frequency (%).
Statistical analysis
For statistical evaluation, Student’s t test was used when
comparing the estrogen-treated mice with the placebo-treated
mice, p values less than 0.05 were considered statistically
significant. When comparing the Ral-, Las-, and Bza-treated
groups with the vehicle-treated group (three comparisons),
Student’s t test with Bonferroni correction was used.
Results
The E2 response in trabecular bone requires ERaAF-1 and
AF-2 whereas the E2 response in cortical bone requires
ERaAF-2 but not AF-1
As expected, the serum testosterone levels in gonadal-intact
(sham) male ERa/ mice were elevated compared to sham WT
controls (WT: 0.68 0.27 ng/mL; ERa/: 5.26 0.88 ng/mL;
p< 0.01; Fig. 1A). These sham ERa/ mice showed a normal
trabecular bone volume/tissue volume (BV/TV; WT: 27.3%
2.1%; ERa/: 26.9% 1.4%; Fig. 1B), but a significantly
decreased cortical thickness (WT: 0.228 0.006mm; ERa/:
Fig. 1. Elevated serum testosterone levels in male ERa/mice lead to compensatory effects in trabecular bone but not in cortical bone. Gonadal-intact
(sham)male ERa/mice and their corresponding shamwild-type (WT) mice were evaluated. (A) Serum testosterone levels were measured. (B) Trabecular
bone (ie, bone volume/tissue volume, BV/TV) in L5 vertebra was analyzed by mCT. (C) Cortical thickness (Crt. Thk) was analyzed by pQCT.
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0.204 0.003mm; p< 0.01; Fig. 1C) compared to sham WT
controls. This is consistent with previous results showing that
compensatory mechanisms via the androgen receptor (AR) can
maintain the trabecular bone mass, but not the cortical bone
mass inmale ERa/mice.(9) To avoid compensatory effects from
elevated serum testosterone acting via the AR when evaluating
the effect of E2, ERa/, ERaAF-20, and ERaAF-10 mice were orx
and treated with either placebo or E2.
DXAmeasurements showed that E2-treated orxWTmice had a
normal estrogenic response on the total body aBMD (Fig. 2). E2
treatment did not increase total body aBMD in the orx ERa/ or
in the orx ERaAF-20 mice. However, E2 treatment led to a
significantly increased total body aBMD in the orx ERaAF-10
mice, although the E2 response was of less magnitude compared
to the E2 response in orx WT mice (Fig. 2).
Trabecular bone analyses of L5 vertebrae, using mCT,
demonstrated a clear estrogenic response in trabecular bone
in orx WT mice (Fig. 3). In contrast, there was no estrogenic
response in orx ERa/, orx ERaAF-20, or orx ERaAF-10 mice.
Cortical bone analyses of femur showed that E2 treatment
increased the cortical thickness and vBMD in orx WT mice
(Fig. 4A, B). The orx ERa/ and orx ERaAF-20 mice showed no
increase in cortical thickness or vBMD when treated with E2.
In contrast, the orx ERaAF-10 mice demonstrated a marked
estrogenic response on both the cortical thickness and vBMD
(Fig. 4A, B). This suggests that the E2 response in trabecular bone
requires both ERaAF-1 and AF-2, whereas the E2 response in
cortical bone requires ERaAF-2 but not AF-1.
Three-point bending tests demonstrated that the stiffness and
the maximal load at failure increased by E2 treatment in the orx
WT mice, but not in orx ERa/ or in orx ERaAF-20 mice (Fig. 4C,
D). Interestingly, the E2-treated orx ERaAF-10 mice showed an
increase in both stiffness and maximal load at failure, although
the increase was not as pronounced as in the orx WT controls
(Fig. 4C, D). Thus, the effect of E2 on bone strength requires
ERaAF-2 but not AF-1.
Role of ERaAF-1 is tissue-dependent
The immune system is known to be involved in the regulation of
bone metabolism; therefore the role of ERaAF-1 and AF-2 for the
E2 response in thymus and bone marrow was investigated. As
expected, the thymus weight, bone marrow cellularity, and the
frequency of B-lymphocytes in the bone marrow were decreased
in E2-treated orx WT mice. No E2 response was seen for thymus
weight or bone marrow parameters in the orx ERa/ or orx
ERaAF-20 mice (Table 1), showing that an intact ERaAF-2 is
required for the effects of E2 on these parameters. Interestingly,
the E2 response in the ERaAF-10 mice varied between the
evaluated parameters. Similarly, as seen for trabecular bone
parameters (BV/TV: 8.1% 7.5% and trabecular number:
4.7% 7.3% of E2 response in WT mice; Fig. 5, Table 1), no
significant E2 response was seen on thymus weight/body weight
(5.7% 9.1% of E2 response in WT mice; Fig. 5, Table 1), and
similar to the E2 response in cortical thickness and vBMD
(32% 5.9% and 45% 6.3% of E2 response in WT mice; Fig. 5)
a clear E2 response was seen for the bone marrow cellularity
(33% 6.3% of E2 response in WT mice; Fig. 5, Table 1) and
frequency of B-lymphocytes (54% 9.6% of E2 response in WT
mice; Fig. 5, Table 1). This suggests that ERaAF-2 is required for all
E2 effects evaluated while the role of ERaAF-1 is tissue-
dependent (Fig. 5).
The effects of SERMs are dependent on ERaAF-1
Orx WT mice were treated with three different SERMs (Ral, Las, or
Bza) or veh to evaluate their effects on bone and other estrogenic
target tissues. These SERMs increased the total body aBMD
and the trabecular vBMD to a similar extent compared to
veh (Fig. 6A, B). All three SERMs appeared to increase cortical
bone parameters compared to vehicle. However, after the
conservative Bonferroni correction (three comparisons), only Las
increased cortical thickness significantly (Ral: þ5.6%, p¼ 0.047;
Las: þ9.9%, p¼ 0.011; and Bza: þ8.1%, p¼ 0.039; Fig. 6C,
Fig. 2. Role of ERaAF-1 and AF-2 for the effect of E2 on total body areal
bone mineral density (aBMD) in orchidectomized (orx) male mice. Total
body aBMD analyzed by DXA in orx ERa/, ERaAF-10, and ERaAF-20
mice and their corresponding orx wild-type (WT) mice after placebo or
estradiol (E2) treatment for 4 weeks. KO¼ knockout. p< 0.05 versus
placebo-treated orx mice, Student’s t test. Values are given as means
SEM (n¼ 8–11).
Fig. 3. Role of ERaAF-1 and AF-2 for the effect of E2 on trabecular bone
volume in orchidectomized (orx) male mice. Trabecular bone (ie, bone
volume/tissue volume [BV/TV]) in L5 vertebra was analyzed by mCT in orx
ERa/, ERaAF-10, and ERaAF-20 mice and their corresponding orx wild-
type (WT) mice after placebo or estradiol (E2) treatment for 4 weeks.
KO¼ knockout. p< 0.05 versus placebo-treated orx mice, Student’s
t test. Values are given as means SEM (n¼ 8–11).
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Bonferroni correction requires p< 0.017 for significance) and
only Bza increased bone strength significantly (maximal load at
failure; Ral: þ7.8%, p¼ 0.285; Las: þ11.3%, p¼ 0.092; and Bza:
þ16.2%, p¼ 0.006; Fig. 6D). None of the SERMs reduced
the thymus weight/body weight (veh: 2.6 0.5mg/g; Ral:
2.5 0.1mg/g; Las: 2.5 0.1mg/g; Bza: 2.6 0.1mg/g).
Our finding, that the role of ERaAF-1 for the effect of E2 is
tissue-dependent in male mice, together with the fact that the
effects of SERMs in vitro have been suggested to be mediated
mainly via the ERaAF-1, led us to evaluate if the ERaAF-1 is
required for different SERMs to exert their effects in vivo.
Therefore, orx ERaAF-10 mice were treated with Ral, Las, Bza, or
veh. None of the treatments; Ral, Las, or Bza, increased total body
aBMD, trabecular bone, cortical bone, or bone strength in the orx
ERaAF-10 mice (Fig. 6A–D). Therefore, the effects of these three
SERMs are dependent on a functional ERaAF-1 in male mice.
Discussion
Estrogens are crucial for male bone health. When serum E2 levels
are below a certain threshold in males, there are indications that
SERM treatment could have positive effects on bone without
having feminizing effects.(1–4,32,33) Hence, it is of importance to
further characterize the signaling pathways of estrogen and
SERMs in male bone, and other estrogenic target tissues, in order
to facilitate the development of new bone-specific treatment
strategies for male osteoporosis. Because the bone-sparing
effects of estrogen in both men and male mice are primarily
mediated via ERa,(4,7) we have evaluated the roles of ERaAF-1
and ERaAF-2 in male mice by using mouse models with specific
deletions of AF-1 or AF-2 in ERa. These specific deletions leave
all other domains of ERa intact, which ensures that ligand can
bind to the receptor and that the receptor can bind to the
DNA.(19,36,40–42) Therefore, the phenotypes of the ERaAF-10 and
ERaAF-20 mice are due to the lack of the specific AF and not
due to inability of the ERaAF-10 and ERaAF-20 proteins to bind
the DNA or the ligand. Ourmain findings in this study are that the
estrogenic effects on all evaluated parameters are dependent
on ERaAF-2, whereas the role of ERaAF-1 for the estrogenic
effects is tissue-specific, where the trabecular bone is dependent
on ERaAF-1 but the cortical bone and bone strength do not
require ERaAF-1. In contrast, all effects of the three evaluated
SERMs require an intact ERaAF-1.
Sex steroids are important for skeletal growth and mainte-
nance in both the female and male skeleton. The effects of
Fig. 4. Role of ERaAF-1 and AF-2 for the effect of E2 on cortical bone parameters and bone strength in orchidectomized (orx) male mice. orx ERa/,
ERaAF-10, and ERaAF-20 mice and their corresponding orx wild-type (WT) mice were treated with placebo or estradiol (E2) for 4 weeks. (A) Cortical
thickness (Crt. Thk.) and (B) cortical volumetric bone mineral density (Crt. vBMD) were analyzed by pQCT. (C) Stiffness and (D) maximal load at failure
(Max. Load) were analyzed by three-point bending. KO¼ knockout. p< 0.05 versus placebo-treated orx mice, Student’s t test. Values are given as
means SEM (n¼ 8–11).
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testosterone can be exerted directly through the AR or indirectly
via aromatization to E2 and activation of ERa, but not ERb, in
male mice.(43,44) When deleting the ERa in male mice, the serum
testosterone levels are elevated due to a disturbed negative
feedback mechanism. These high testosterone levels have
compensatory effects on the skeleton via activation of the
AR.(9,45) When evaluating the results for the intact, sham-
operated, male mice it was clear that ERa was necessary to
maintain cortical thickness, whereas the elevated testosterone
levels could prevent the trabecular bone loss (BV/TV) in mice
devoid of ERa.
To analyze the importance of different domains of ERa for the
estrogenic effects in male mice without having confounding
compensatory effects of elevated serum testosterone, ERa/,
ERaAF-20, ERaAF-10, and control WT mice were orx and treated
with either placebo or E2. As expected, E2 increased the total
body aBMD in all orx WT control mice and this was due to an
increase in both trabecular and cortical bone mass. In contrast,
no effect on any of these bone parameters was seen in the orx
ERa/ or in the orx ERaAF-20 mice. This demonstrates that ERa,
is of importance in the male skeleton and that ERaAF-2 is crucial
for the estrogenic effects in both trabecular and cortical bone.
Interestingly, there was a significant effect of E2 on total body
aBMD in the orx ERaAF-10 mice. Further analyses of the
trabecular and cortical bone of these mice showed that the orx
ERaAF-10 mice had no E2 response in the trabecular bone
whereas they had a clear response to E2 in the cortical bone.
These results are consistent with a previous study in female
mice.(36) Because cortical bone comprises more than 80% of the
skeleton and is increasingly recognized as a major structural
determinant of bone strength,(1) we continued to analyze the
effect of E2 on the biomechanical properties of the three male
knockout mouse models. We concluded that all E2-treated orx
WT mice showed an increase in bone strength. The increase in
cortical bone mass in the E2-treated orx ERaAF-10 mice also led
to an increased bone strength, whereas there was no E2 effect
on these parameters in the orx ERa/ or orx ERaAF-20 mice.
Therefore, ERaAF-1 is not required for an estrogenic effect on
bone strength.
The immune system is known to be involved in the regulation
of bone metabolism; therefore the role of ERaAF-2 and ERaAF-1
for the E2 response in bone marrow and thymus was
investigated. The orx WT mice had a normal estrogenic response
on bone marrow cellularity and thymus weight, whereas there
was no E2 response on these parameters in the orx ERa/ or in
the orx ERaAF-20 mice. The orx ERaAF-10 mice displayed an
estrogenic response on the bone marrow cellularity and on the
frequency of B-lymphocytes in the bone marrow, whereas they
had no response on the thymus weight. This demonstrates that
the E2 response on bone marrow cellularity and on the
percentage of B-lymphocytes in the bonemarrow inmale mice is
dependent on ERaAF-2 but not on AF-1, whereas the thymus
weight is dependent on both ERaAF-2 and AF-1.
SERMs have been shown to increase BMD in men with low
BMD(32,33) and there are studies in orx mice and orx rats that have
shown that both Ral and Las have an effect on male bone
mass.(46,47) Here, we have for the first time in orx male mice,
evaluated the effects of the three SERMs; Ral, Las, and Bza in theT
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same study and evaluated their effects on several bone
parameters and thymus weight. These three SERMs increased
total body aBMD and trabecular bone mass in orx WT mice to a
similar extent. Las-treated orx WT mice showed a significant
increase in cortical thickness, whereas Ral- and Bza-treated mice
had a tendency toward an increase. Bza-treated orx WT mice
displayed significantly increased bone strength as analyzed by
three-point bending, and there was a tendency toward an
increase in the Ral- and Las-treated mice. Our results indicate
that Las and Bza treatment increase cortical bone parameters
more than Ral treatment. This is consistent with the fact that Las
and Bza, but not Ral, have been shown to have significant effects
on nonvertebral fractures.(27,29–31)
Our study demonstrates that the estrogenic effects of ERa
AF-1 are tissue-dependent in male mice, whereas the estrogenic
effects of ERaAF-2 are crucial for all evaluated parameters. In
addition, the three SERMs; Ral, Las, and Bza exert tissue-specific
effects in orx WT mice. Taken together, these results led us to
further evaluate the importance of ERaAF-1 for different SERMs
to exert their effects in vivo, by evaluating the effects of Ral, Las,
and Bza in orx ERaAF-10 mice. Our results show that there are no
agonistic effects of the SERMs when ERaAF-1 is deleted. This
finding further strengthens the theory that it is the ERaAF-1 that
mainly mediates the tissue-specific effects of the SERMs, and that
the SERM interactions with ERb cannot replace ERa in the
evaluated tissues in these male mice. When E2 binds to the
ligand binding domain of ERa, helix 12 is folded in the agonistic
orientation. This enables helices 3, 4, 5, and 12 to form the
ERaAF-2 hydrophobic patch to which coactivators can bind,
where the most important interaction site is found in helix 12.
Fig. 5. The role of ERaAF-1 is tissue-dependent. Orchidectomized (orx)
ERaAF-10 mice and their corresponding orx wild-type (WT) mice were
treated with placebo or estradiol (E2) for 4 weeks. As expected, E2
treatment resulted in a significant effect on several estrogen-responsive
bone parameters (increased total body areal bone mineral density
[aBMD], cortical thickness, cortical volumetric BMD [vBMD], trabecular
bone volume/tissue volume [BV/TV], trabecular number [N]), bone mar-
row parameters (reduced bone marrow [BM] cellularity and frequency of
B-lymphocytes), and non-bone parameters (reduced thymus weight) in
orx WT mice. To illustrate the role of ERaAF-1 for the effect of E2 on these
parameters, the estrogenic response in E2-treated orx WT mice, for each
parameter, is set to 100%. The bars represent the estrogenic response in
percent for the E2-treated orx ERaAF-10 mice compared with the E2
response in orx WT mice. Thus, 0% means no E2 response whereas 100%
is a normal WT E2 response. The results show that whereas some
parameters are dependent on a functional ERaAF-1, many do not require
ERaAF-1 for an estrogenic response. Values are means SEM (n¼ 8–11).
Fig. 6. Tissue-specific effects of selective estrogen receptor modulators (SERMs) in wild-type (WT) mice are dependent on ERaAF-1. Orchidectomized (orx)
WT and ERaAF-10 mice were treated with vehicle (Veh), Raloxifene (Ral), Lasofoxifene (Las), or Bazedoxifene (Bza) for 3 weeks. (A) Total body areal bone
mineral density (aBMD) was analyzed by DXA. Trabecular volumetric BMD (Trab. vBMD) (B) and cortical thickness (Crt. Thk.) (C) were analyzed by pQCT. (D)
Maximal load at failure (Max. Load) was analyzed with a three-point bending test. p< 0.05 versus corresponding Veh-treated orx mice, Student’s t test
Bonferroni corrected. Values are means SEM (n¼ 6–10).
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However, when a SERM binds to the ERa, helix 12 in the ligand
binding domain is prevented from folding in the agonistic
orientation and the ERaAF-2 hydrophobic patch is not formed
correctly. Instead, helix 12 is able to bind to the static region of
AF-2; formed by residues from helices 3, 4, and 5. This leads to a
limitation and/or loss of interaction between ERaAF-2 and its
corepressors and coactivators.(48–50) Consequently, when ERaAF-
1 is deleted, the interaction of coactivators with any of the two
AFs in ERa, after SERM activation, is greatly affected and little or
no regulation of ERa-dependent gene transcription will occur in
the evaluated tissues. Because there was no response in ERaAF-
10 mice, on bone parameters or thymus weight, after SERM
treatment, we conclude that the ERaAF-1 probably is the most
important mediator for the effects of the presently evaluated
SERMs, but it is possible that some other region/regions of ERa
are also involved. The lack of E2 response in the ERaAF-20 mice
suggests that ERaAF-1 is not able to activate the ERaAF-20
protein. The ERaAF-20 protein lacks the most important
coactivator interaction site in the ERaAF-2 hydrophobic patch,
found in helix 12. This suggests that it is not possible for
coactivators to bind to the ERaAF-20 protein, whereas
corepressors are still able to interact with the static region of
AF-2. Therefore, corepresssor binding to the ERaAF-20 protein
could prevent the ERaAF-1 from activating ERa, thereby
inhibiting estrogenic responses in the E2 treated ERaAF-20
mice. In contrast, when a SERM binds to the full length ERa the
binding of helix 12 to the static region of AF-2 prevents
corepresssor interaction.(48–52)
In conclusion, ERaAF-2 is required for all the evaluated
estrogenic effects in orx male mice, whereas the role of AF-1 is
tissue-specific, where the trabecular bone is dependent on
ERaAF-1 but the cortical bone and bone strength do not require
ERaAF-1. In addition, the tissue-specific effects of Ral, Las, and
Bza are dependent on ERaAF-1. These results further clarify the
signaling pathways of E2 and SERMs via different domains of ERa
in male mice, which suggest that it would be beneficial to
develop a new class of SERMs that, in contrast to the SERMs
presently available, would not activate the ERaAF-1. This SERM
would have positive effects on the cortical bone and bone
strength, while minimizing the adverse effects in other tissues.
Importantly, cortical bone comprises more than 80% of the
skeleton and is likely the major contributor to overall fracture
risk. To screen for such new SERMs, the ERaAF-10 mice will be a
valuable model for evaluating the effects of the SERMs in vivo.
The results from this study could facilitate the design of novel,
bone-specific SERMs for male osteoporosis.
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